Digipath Labs’ Mission
Digipath Labs’ mission is to provide pharmaceutical-grade analysis and testing to the cannabis industry to ensure consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its client’s products through research, development, and standardization.
Laboratory testing is one of the vital platform technologies in the cannabis marketplace and must become standardized, consistent, and robust in order to maintain the long term health of the cannabis industry. From its inception, Digipath Labs’ mission has been to facilitate an industry-wide mandate that medical cannabis adhere to the same standards as other food and drug markets. A diverse array of assays and state-of-the-art, FDA-compliant lab equipment enables the Company to accurately test cannabis in accordance with Good Lab Practices.
Dr. Cindy Orser, Ph.D., a 20-year biotech and diagnostic industry veteran, leads these efforts on behalf of Digipath, serving as Chief Science Officer and assists cannabis providers and regulatory agencies, as well as working in academia in several key roles. In addition to her work, she holds 18 patents and authored 41 peer-reviewed publications.
Digipath Labs began earning substantive revenue in October 2015 and has been growing quarter after quarter ever since. As of January 2018, we have tested more than 17,000 cannabis product samples, from many of the 88 growers and 57 producers licensed by the State of Nevada.